MX2022004059A - Induction of immunity to sars-cov-2 in children. - Google Patents

Induction of immunity to sars-cov-2 in children.

Info

Publication number
MX2022004059A
MX2022004059A MX2022004059A MX2022004059A MX2022004059A MX 2022004059 A MX2022004059 A MX 2022004059A MX 2022004059 A MX2022004059 A MX 2022004059A MX 2022004059 A MX2022004059 A MX 2022004059A MX 2022004059 A MX2022004059 A MX 2022004059A
Authority
MX
Mexico
Prior art keywords
seq
cov
induction
adenovirus serotype
sars
Prior art date
Application number
MX2022004059A
Other languages
Spanish (es)
Inventor
Olga Popova
Aleksandr Sergeevich Semikhin
Olga Vadimovna Zubkova
Tatiana Andreevna Ozharovskaia
Inna Vadimovna Dolzhikova
Dmitrii Viktorovich Shchebliakov
Daria Mikhailovna Grousova
Alina Shahmirovna Dzharullaeva
Amir Ildarovich Tukhvatulin
Natalia Mikhailovna Tukhvatulina
Dmitrii Nikolaevich Shcherbinin
Ilias Bulatovich Esmagambetov
Elizaveta Alexandrovna Tokarskaya
Andrei Gennadevich Botikov
Sergey Vladimirovich Borisevich
Denis Yuryevich Logunov
Aleksandr Leonidovich Gintsburg
Fatima Magomedovna Izhaeva
Nadezhda Leonidovna Lubenets
Boris Savelievich Naroditsky
Vladimir Aleksandrovich Chernetsov
Evgenii Vladimirovich Kriukov
Vladimir Fedorovich Babira
Alina Sergeevna Erokhova
Natalia Anatolievna Nikitenko
Dmitrii Anatolievich Kutaev
Svetlana Yakovlevna Loginova
Original Assignee
Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021134724A external-priority patent/RU2761904C1/en
Application filed by Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte filed Critical Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte
Publication of MX2022004059A publication Critical patent/MX2022004059A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Group of invention relates to biotechnology, immunology and virology. Described is the use of an agent containing expression vector based on strain human adenovirus serotype 26 or human adenovirus serotype 5, in which E1 and E3 regions are deleted, with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, or simian adenovirus serotype 25, in which E1 and E3 regions are deleted with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3 or contains only component 2 for for induction of specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in children aged 1 month and older.
MX2022004059A 2021-11-26 2022-02-18 Induction of immunity to sars-cov-2 in children. MX2022004059A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2021134724A RU2761904C1 (en) 2021-11-26 2021-11-26 Drug application for induction of specific immunity against severe acute respiratory syndrome virus sars-cov-2 in children
PCT/RU2022/000047 WO2022197209A1 (en) 2021-11-26 2022-02-18 Induction of immunity to sars-cov-2 in children

Publications (1)

Publication Number Publication Date
MX2022004059A true MX2022004059A (en) 2022-10-18

Family

ID=81845591

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004059A MX2022004059A (en) 2021-11-26 2022-02-18 Induction of immunity to sars-cov-2 in children.

Country Status (8)

Country Link
EP (1) EP4436599A1 (en)
JP (1) JP2023512381A (en)
KR (1) KR20240135414A (en)
CN (1) CN116528895A (en)
CA (1) CA3156264A1 (en)
IL (1) IL291816B2 (en)
MX (1) MX2022004059A (en)
ZA (1) ZA202203566B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2731342C9 (en) * 2020-08-22 2021-10-05 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Pharmaceutical agent and method for use thereof for inducing specific immunity to virus of severe acute respiratory syndrome sars-cov-2 (embodiments)

Also Published As

Publication number Publication date
IL291816B1 (en) 2024-03-01
EP4436599A1 (en) 2024-10-02
IL291816A (en) 2022-06-01
KR20240135414A (en) 2024-09-11
CN116528895A (en) 2023-08-01
CA3156264A1 (en) 2022-10-24
ZA202203566B (en) 2023-11-29
IL291816B2 (en) 2024-07-01
JP2023512381A (en) 2023-03-27

Similar Documents

Publication Publication Date Title
Krug et al. The progressive adaptation of a georgian isolate of African swine fever virus to vero cells leads to a gradual attenuation of virulence in swine corresponding to major modifications of the viral genome
AR121931A1 (en) IMMUNOBIOLOGICAL AGENT AND METHOD OF USE THEREOF TO INDUCE SPECIFIC IMMUNITY AGAINST SARS-CoV-2 SEVERE ACUTE RESPIRATORY SYNDROME VIRUS (VARIANTS)
SA519402565B1 (en) Novel adeno-associated virus clade f vector and uses therefor
Thammawat et al. Role of cellular glycosaminoglycans and charged regions of viral G protein in human metapneumovirus infection
ZA202301438B (en) Aa v5-based vaccine against sars-cov-2
WO2021000968A3 (en) Adenovirus carrier vaccine used for preventing sars-cov-2 infection
ZA202202322B (en) Expression vector against severe acute respiratory syndrome virus sars-cov-2
BR0111366A (en) Recombinant Porcine Respiratory and Respiratory Syndrome Virus (prrsv) Vaccine
MX2022003069A (en) Agent for inducing specific immunity against sars-cov-2.
Stoermer Burrack et al. Attenuating mutations in nsP1 reveal tissue-specific mechanisms for control of Ross River virus infection
Waku Kouomou et al. Adaptation of wild-type measles virus to tissue culture
UY39582A (en) VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY AGAINST SARSCOV-2 AND/OR THE PREVENTION OF SARSCOV-2 RELATED CORONAVIRUS INFECTION
Cox et al. A single mutation at PB1 residue 319 dramatically increases the safety of PR8 live attenuated influenza vaccine in a murine model without compromising vaccine efficacy
Cook et al. Enhancement of equine infectious anemia virus virulence by identification and removal of suboptimal nucleotides
Evans et al. Challenges and prospects in developing future SARS-CoV-2 vaccines: Overcoming original antigenic sin and inducing broadly neutralizing antibodies
MX2022004059A (en) Induction of immunity to sars-cov-2 in children.
Ahmed et al. Individual and synergistic anti-coronavirus activities of SOCS1/3 antagonist and interferon α1 peptides
MX2022016287A (en) Gorilla adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof.
Szarpak et al. Variant lambda of the severe acute respiratory syndrome coronavirus 2: A serious threat or the beginning of further dangerous mutations
Wang et al. Glycosaminoglycan binding properties of natural Venezuelan equine encephalitis virus isolates
MX2021000949A (en) New attenuated virus strain and use thereof as a vaccine.
MX2022003963A (en) The use of the agent for inducing immunity to sars-cov-2.
MX2022004060A (en) The use of the agent for inducing immunity to sars-cov-2.
BR112022004778A2 (en) AGENT FOR SPECIFIC IMMUNITY INDUCTION AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARSCOV-2 IN LYOPHILIZED FORM (VARIANTS) AND USE
Ma et al. The middle half genome of interferon-inducing porcine reproductive and respiratory syndrome virus strain A2MC2 is essential for interferon induction